Tvardi Therapeutics, Inc.

TVRD Nasdaq SEC CIK 1346830
Follow Tvardi Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$6.1M −10.8% vs same quarter last year
EPS, diluted −$0.48 +18.6% vs same quarter last year
Operating cash flow −$6.4M −49.9% vs same quarter last year
Operating income −$6.3M −6.6% vs same quarter last year
Revenue by quarter
$1.5M
$2.6M
Q4 24 Q1 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$18.2M
FY24$7.1M−$29.4M
FY23$21M−$11.9M
FY22$41.9M−$85.5M
FY21$23M−$88.4M
FY20$135.1M$8.4M
FY19$19.9M−$106.4M
FY18$13.5M−$74M
FY17$911K−$58.1M
FY16$86K−$57.3M
FY15$3.8M−$24.7M
FY14$3.2M−$17.7M
FY13$12M−$4M
FY12$1.2M−$6.3M
FY11--
MarginsShare of revenue
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%20000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24−393.8%−411.9%
FY23−579.4%−56.5%
FY22−209.1%−204.2%
FY21−386.8%−384.1%
FY204%6.2%
FY19−561.6%−534.9%
FY18−574.5%−549.5%
FY17−6529.6%−6380.4%
FY16−67907%−66604.7%
FY15−662.3%−649.2%
FY14−568.8%−558.5%
FY13−2%−33.1%
FY12−524%−527%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$19.4M
FY23−$94.5M
FY22−$78.8M
FY21−$60.1M
FY20−$5.8M
FY19−$109.2M
FY18−$22.4M
FY17−$54.9M
FY16−$48.1M
FY15−$21.5M
FY14−$17.7M
FY13$2.8M
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Tvardi Therapeutics
  • Healthcare median
−80000%−60000%−40000%−20000%0%20000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearTvardi TherapeuticsHealthcare median
FY25-−30.6%
FY24−411.9%−47%
FY23−56.5%−58%
FY22−204.2%−80.4%
FY21−384.1%−71.8%
FY206.2%−62.2%
FY19−534.9%−46.2%
FY18−549.5%−49.6%
FY17−6380.4%−45.9%
FY16−66604.7%−36%
FY15−649.2%−37.8%
FY14−558.5%−35.5%
FY13−33.1%−37.1%
FY12−527%−29.1%
FY11-−27.9%